Related Experiment Videos
Inhaled steroids in patients with bronchiectasis.
J S Elborn1, B Johnston, F Allen
1Respiratory Medicine Unit, Belfast City Hospital, Northern Ireland, U.K.
Respiratory Medicine
|March 1, 1992
Summary
Inhaled beclomethasone diproprionate significantly reduced sputum production and improved cough symptoms in patients with bronchiectasis. While lung function showed minor improvements, the primary benefits were decreased mucus and better symptom control.
Area of Science:
- Pulmonology
- Pharmacology
Background:
- Bronchiectasis is a chronic respiratory condition characterized by persistent cough and sputum production.
- Current management strategies aim to reduce exacerbations and improve quality of life.
Purpose of the Study:
- To evaluate the efficacy of inhaled beclomethasone diproprionate in patients with bronchiectasis.
- To assess its impact on sputum production, pulmonary function, and symptom scores.
Main Methods:
- A double-blind, placebo-controlled, cross-over study was conducted.
- Twenty patients with bronchiectasis received inhaled beclomethasone diproprionate (1500 micrograms/day) or placebo.
Main Results:
- An 18% reduction in daily sputum production was observed with inhaled steroids (P < 0.003).
- Significant improvement in cough symptom scores (P < 0.02) was noted.
- Minor, clinically insignificant improvements in lung function (PEFR, FEV1) were observed.
Conclusions:
- Inhaled beclomethasone diproprionate effectively reduces sputum production in bronchiectasis.
- It may serve as a valuable adjunct therapy for managing cough and mucus in these patients.